Agenus Inc. (AGEN)
-NasdaqCM 4.25 
0.01(0.23%) 18 May 04:00 SGT
| Prev Close: | 4.26 |
|---|
| Open: | 4.21 |
|---|
| Bid: | 3.52 x 100 |
|---|
| Ask: | 4.60 x 3300 |
|---|
| 1y Target Est: | 10.63 |
|---|
| Beta: | 2.29 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 4.16 - 4.29 |
|---|
| 52wk Range: | 3.37 - 5.99 |
|---|
| Volume: | 134,629 |
|---|
| Avg Vol (3m): | 159,163 |
|---|
| Market Cap: | 107.52M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -1.13 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- AGENUS INC FinancialsEDGAR Online Financials(Sat, 01:04 SGT)
- AGENUS INC Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, 10 May)
- Positive Phase 2 Data from Agenus' Brain Cancer Vaccine Presented at Plenary Session of American Academy of Neurological Surgeons MeetingGlobeNewswire(Wed, 1 May)
- AGENUS INC Files SEC form 8-K, Other Events, Financial Statements and ExhibitsEDGAR Online(Wed, 1 May)
- Agenus: Near-Term Drivers With A Market Opportunity Over $17 Billionat Seeking Alpha(Mon, 29 Apr)
- Agenus' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, 25 Apr)
- Quickly Approaching Biopharma Catalyst Eventsat Seeking Alpha(Wed, 24 Apr)
- Q1 2013 Antigenics Inc. Earnings Release - Before Market OpenCCBN(Wed, 24 Apr)
- Agenus Reports First Quarter 2013 Financial ResultsGlobeNewswire(Wed, 24 Apr)
- AGENUS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and ExhibitsEDGAR Online(Wed, 24 Apr)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 29.17 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.96 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.22 |
|---|
| Mean Recommendation*: | 1.8 |
|---|
| PEG Ratio (5 yr expected): | N/A |
|---|
Business Summary
Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies.
View More